Johnson & Johnson vs. ARS Pharmaceuticals, Inc. Common Stock
Johnson & Johnson (JNJ) comes out ahead, leading on 7 of 8 compared factors.
Size & Scale
| JNJ | SPRY | |
|---|---|---|
| Market Cap | $663.28 billion | $558.89 million |
| Revenue (TTM) | $97.93 billion | $116.93 million |
| Net Income (TTM) | $21.04 billion | $-215,432,000 |
JNJ leads on 3 of 3 size & scale factors.
Valuation
| JNJ | SPRY | |
|---|---|---|
| P/E Ratio | 31.93 | — |
| Price / Book | 7.81 | 44.67 |
| Price / Sales | 6.77 | 4.78 |
JNJ and SPRY split the valuation factors evenly.
Profitability
| JNJ | SPRY | |
|---|---|---|
| Net Margin | 21.48% | -184.24% |
| Return on Equity | 24.76% | -1721.80% |
JNJ leads on 2 of 2 profitability factors.
Dividend
| JNJ | SPRY | |
|---|---|---|
| Dividend Yield | 1.95% | — |
| Payout Ratio | 62.18 | — |
JNJ and SPRY split the dividend factors evenly.
Risk & Sentiment
| JNJ | SPRY | |
|---|---|---|
| Short Interest | 0.67% | 0.82% |
JNJ leads on 1 of 1 risk & sentiment factors.
Dig deeper: JNJ overview, JNJ financials, SPRY overview, SPRY financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.